

# Financial Tear Sheet

## Corporate Profile

Forward Pharma A/S is a Danish biopharmaceutical company that commenced development in 2005 of FP187, a proprietary formulation of DMF for the treatment of inflammatory and neurological indications. The Company owns a significant intellectual property (IP) portfolio related to DMF formulations. The Company granted to Biogen an irrevocable license to all of its IP through the recent License Agreement and received from Biogen a non-refundable cash fee of \$1.25 billion in February 2017. The Company has the opportunity to receive royalties from Biogen on sales of Tecfidera® or other DMF products for MS, dependent on, among other things, successfully appealing the U.S. interference and a favorable outcome in Europe with respect to the EP2801355 opposition proceeding.

## Stock Performance

### FWP (Common Stock)

**Exchange** NASDAQ GS (US Dollar)

**Financial Status Indicator** C

**Price** **\$19.47**

**Change (%)** ▼ 0.22 (1.12%)

**Volume** 3,642

**52 Week Low** \$14.89

**Market Cap** \$917,891,519

**Rolling EPS** -0.71

**PE Ratio** 0

**Shares Outstanding** 47,143,889



Data as of 05/26/17 4:00 p.m. ET

## Recent Headlines

05/01/17

Forward Pharma CEO to Present at the 42nd Annual Deutsche Bank Health Care Conference on May 4, 2017

---

05/01/17

Forward Pharma Further Aligns Cost Structure with Focus Following Settlement and License Agreement

---

04/18/17

Forward Pharma Reports Fourth Quarter and Year End 2016 Financial and Operational Results

---

## Upcoming Events

<b>Date</b>	<b>Title</b>
06/06/17 3:00 p.m. ET	<b>Forward Pharma A/S at Jefferies 2017 Global Healthcare Conference</b> <b>Location</b> New York, NY
06/20/17 3:30 p.m. ET	<b>Forward Pharma A/S at JMP Securities Life Sciences Conference</b> <b>Location</b> New York, NY

---

## SEC Filings

<b>Filing Date</b>	<b>Form</b>	<b>Corporate Governance</b>	
		Claus Bo Svendsen, MD, PhD	CEO
05/04/17	6-K	Peder Møller Andersen, MD	COO
05/03/17	6-K		
05/01/17	6-K		
04/19/17	6-K		

---

*Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources*